• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gain Therapeutics Inc (NQ: GANX )

    2.960 +0.030 (+1.02%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 96,022
    Open 3.000
    Bid (Size) 2.960 (1)
    Ask (Size) 3.440 (1)
    Prev. Close 2.930
    Today's Range 2.870 - 3.020
    52wk Range 2.000 - 5.650
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
    From Gain Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -18.34%
    -18.34%
    1 Month
    -25.81%
    -25.81%
    3 Month
    -24.87%
    -24.87%
    6 Month
    +3.14%
    +3.14%
    1 Year
    -42.52%
    -42.52%

    More News

    Read More
    Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Gain Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Present at Public Ventures Discovery Day
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
    Via Benzinga
    Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Gain Therapeutics Announces Proposed Public Offering
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.